AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 101 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,145 | -34.5% | 20,597 | +4.9% | 0.00% | -100.0% |
| Q2 2023 | $323,663 | +105.4% | 19,640 | +14.2% | 0.00% | – |
| Q1 2023 | $157,561 | +23.5% | 17,201 | -3.4% | 0.00% | – |
| Q4 2022 | $127,580 | +57.5% | 17,801 | +10.6% | 0.00% | – |
| Q3 2022 | $81,000 | +1520.0% | 16,101 | +657.3% | 0.00% | – |
| Q2 2022 | $5,000 | -66.7% | 2,126 | 0.0% | 0.00% | – |
| Q1 2022 | $15,000 | -16.7% | 2,126 | -2.9% | 0.00% | – |
| Q4 2021 | $18,000 | -14.3% | 2,189 | +1.1% | 0.00% | – |
| Q3 2021 | $21,000 | -69.6% | 2,166 | -78.8% | 0.00% | – |
| Q2 2021 | $69,000 | -31.7% | 10,213 | -8.9% | 0.00% | – |
| Q1 2021 | $101,000 | +34.7% | 11,213 | 0.0% | 0.00% | – |
| Q4 2020 | $75,000 | -6.2% | 11,213 | -29.7% | 0.00% | – |
| Q3 2020 | $80,000 | +66.7% | 15,951 | +165.8% | 0.00% | – |
| Q2 2020 | $48,000 | +700.0% | 6,000 | +757.1% | 0.00% | – |
| Q1 2020 | $6,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,498,838 | $22,889,355 | 11.72% |
| Knoll Capital Management, LLC | 500,000 | $4,580,000 | 7.06% |
| GENDELL JEFFREY L | 5,301,914 | $48,565,532 | 4.55% |
| COWEN AND COMPANY, LLC | 3,732,778 | $34,192,246 | 4.02% |
| Tri Locum Partners LP | 1,327,097 | $12,156,209 | 3.70% |
| Samsara BioCapital, LLC | 1,409,409 | $12,910,186 | 2.67% |
| Altium Capital Management LP | 500,000 | $4,580,000 | 2.54% |
| Vivo Capital, LLC | 3,761,438 | $34,454,772 | 2.39% |
| RTW INVESTMENTS, LP | 5,741,939 | $52,596,161 | 1.10% |
| Knott David M Jr | 291,113 | $2,667 | 1.05% |